Key findings from the Phase 2 trial included: Dose-dependent weight loss , with greater reductions observed at higher doses Significant improvements in waist circumference , blood pressure , and lipid profiles Reductions in fasting glucose and insulin resistance markers, though the clinical significance of these findings in people with type 2 diabetes requires further investigation Weight loss appeared to continue throughout the 48-week period without a clear plateau at the highest doses Whilst these results are encouraging, it is important to contextualise them appropriately
When combined with semaglutide, the two peptides work through dual-pathway modulation, targeting both the incretin and amylin networks simultaneously
Cyanocobalamin, or vitamin B12, is sometimes included because it can reduce injection-site discomfort for some patients and may support those who are B12-deficient
The Wegovy pill has also been approved to reduce cardiovascular risks, similar to the injectable version
"Genetics of melanocytic nevi"